Date: 2013-01-09
Type of information:
phase:
Announcement:
Company: VolitionRx (Singapore) Wales Cancer Bank (UK)
Product: NuQ® tests (Nucleosomics® diagnostic products)
Action mechanism:
Disease: breast cancer
colorectal cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On January 9, 2013, VolitionRx, a life sciences company focused on developing blood-based diagnostic tests, has announced that it will commence a large internal clinical study for its Nucleosomics® diagnostic products this month. This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition’s laboratory on patient blood samples supplied by the Wales Cancer Bank, which is based in Cardiff, in the United Kingdom.
Beginning late January, NuQ® tests will be conducted on blood samples taken from more than 800 cancer patients by the Wales Cancer Bank as well as healthy control volunteers. The expected sample distribution is as follows:
•Breast cancer: approx. 550 patients with a variety of subtypes, including invasive ductal carcinoma, invasive lobular and tubular carcinomas, and in-situ carcinoma ductal
•Colorectal cancer: approx. 230 patients with a variety of subtypes, at various stages from Stage A to Stage D
•Plus smaller numbers of patients with lung and pancreatic cancers.
The study follows a pilot study on 100 patient samples from the Wales Cancer Bank, (results of which were announced in December 2012), after which Volition was awarded scientific approval from the Bank for the number of patients needed for a full scale clinical trial.
Jake Micallef, Chief Scientific Officer of VolitionRx, says: “These larger studies follow successful completion of our own internal pilot studies. This is the next step in obtaining European market approval for Nucleosomics diagnostic tests (beginning with the patient numbers needed for breast and colorectal cancer), and establishing them in routine clinical use.”
In addition to this trial, Volition is currently undertaking four trials: three multi-cancer trials currently underway at Rheinische Friedrich-Wilhelms-Universität Bonn, Germany; and a study into colorectal cancer at CHU-UCL Mont-Godinne Hospital, Belgium.
